Have a personal or library account? Click to login
PD-1 Blockage Facilitates Cytotoxic T and NK Cells Tumoricidal Phenotype in a Murine Breast Carcinoma Cover

PD-1 Blockage Facilitates Cytotoxic T and NK Cells Tumoricidal Phenotype in a Murine Breast Carcinoma

EABR. Experimental and Applied Biomedical Research
AHEAD OF PRINT
By: Sanja Tripković,  Miodrag Jocić,  Isidora Stanisavljević,  Marina Jovanović,  Milena Jurišević,  Andjela Petrović,  Milan Jovanović,  Boško Milev,  Veljko Marić and  Marina Jovanović  
Open Access
|Aug 2023

References

  1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3): 209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4.
    Search in Google ScholarBack to article
  2. Internet site: https://gco.iarc.fr/today/data/factsheets/populations/688-serbia-fact-sheets.pdf
    Search in Google ScholarBack to article
  3. Brown L, Carr MJ, Sam C, Sun W, Whiting J, Kim Y, et al. Tolerance and Outcomes of Neoadjuvant Chemotherapy in Geriatric Breast Cancer Patients. J Surg Res. 2023; 283: 329-335. doi:10.1016/j.jss.2022.10.092.
    Search in Google ScholarBack to article
  4. Guo YQ, Ju QM, You M, Liu Y, Yusuf A, Soon LK. Depression, anxiety and stress among metastatic breast cancer patients on chemotherapy in China. 2023; 22(1): 33. doi: 10.1186/s12912-023-01184-1.
    Search in Google ScholarBack to article
  5. Wang J, Seebacher N, Shi H, Kan Q, Duan Z. Novel strategies to prevent the development of multidrug resistance (MDR) in cancer. Oncotarget. 2017; 8(48): 84559-71. doi: 10.18632/oncotarget.19187.
    Search in Google ScholarBack to article
  6. Hu Y, Li Y, Yao Z, Huang F, Cai H, Liu H, et al. Immunotherapy: Review of the Existing Evidence and Challenges in Breast Cancer. Cancers (Basel). 2023; 15(3): 563. doi: 10.3390/cancers15030563.
    Search in Google ScholarBack to article
  7. Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018; 359: 1350-1355. doi: 10.1126/science.aar4060.
    Search in Google ScholarBack to article
  8. Ishida Y, Agata Y, Shibahara K, Honjo T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 1992; 11(11): 3887-95. doi: 10.1002/j.1460-2075.1992.tb05481.x.
    Search in Google ScholarBack to article
  9. Mariotti FR, Petrini S, Ingegnere T, Tumino N, Besi F, Scordamaglia F, et al. PD-1 in human NK cells: evidence of cytoplasmic mRNA and protein expression. Oncoimmunology. 2018; 8(3): 1557030. doi: 10.1080/2162402X.2018.1557030.
    Search in Google ScholarBack to article
  10. Pesce S, Greppi M, Tabellini G, Rampinelli F, Parolini S, Olive D, et al. Identification of a subset of human natural killer cells expressing high levels of programmed death 1: A phenotypic and functional characterization. J Allergy Clin Immunol. 2017; 139 (1): 335-346.e3. doi: 10.1016/j.jaci.2016.04.025.
    Search in Google ScholarBack to article
  11. Gutic B, Bozanovic T, Mandic A, Dugalic S, Todorovic J, Stanisavljevic D, et al. Programmed cell death-1 and its ligands: Current knowledge and possibilities in immunotherapy. Clinics (Sao Paulo). 2023; 78: 100177. doi: 10.1016/j.clinsp.2023.100177.
    Search in Google ScholarBack to article
  12. Nie X, Chen W, Zhu Y, Huang B, Yu W, Wu Z, et al. B7-DC (PD-L2) costimulation of CD4+ T-helper 1 response via RGMb. Cell Mol Immunol. 2018; 15(10): 888-97. doi: 10.1038/cmi.2017.17.
    Search in Google ScholarBack to article
  13. Hoffmann O, Wormland S, Bittner AK, Collenburg M, Horn PA, Kimmig R, et al. Programmed death receptor ligand-2 (PD-L2) bearing extracellular vesicles as a new biomarker to identify early triple-negative breast cancer patients at high risk for relapse. J Cancer Res Clin Oncol. 2023; 149(3):1159-74. doi: 10.1007/s00432-022-039 80-9.
    Search in Google ScholarBack to article
  14. Ohaegbulam KC, Assal A, Lazar-Molnar E, Yao Y, Zang X. Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. Trends Mol Med. 2015; 21 (1): 24-33.
    Search in Google ScholarBack to article
  15. Vaddepally RK, Kharel P, Pandey R, Garje R, Chandra AB. Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence. Cancers (Basel). 2020; 12 (3): 738.
    Search in Google ScholarBack to article
  16. Schildberg FA, Klein SR, Freeman GJ, Sharpe AH. Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family. Immunity. 2016; 44 (5): 955-72.
    Search in Google ScholarBack to article
  17. Borst J, Ahrends T, Bąbała N, Melief CJM, Kastenmüller W. CD4+ T cell help in cancer immunology and immunotherapy. Nat Rev Immunol. 2018; 18 (10): 635-47.
    Search in Google ScholarBack to article
  18. Farhood B, Najafi M, Mortezaee K. CD8+ cytotoxic T lymphocytes in cancer immunotherapy: A review. J Cell Physiol. 2019; 234 (6): 8509-21.
    Search in Google ScholarBack to article
  19. Pathria P, Louis TL, Varner JA. Targeting Tumor-Associated Macrophages in Cancer. Trends Immunol. 2019; 40 (4): 310-27
    Search in Google ScholarBack to article
  20. Alper KM, Gunes E. The untold story of IFN-γ in cancer biology. Cytokine Growth Factor Rev. 2016; 31: 73-81.
    Search in Google ScholarBack to article
  21. Mandal R, Şenbabaoğlu Y, Desrichard A, Havel JJ, Dalin MG, Riaz N, et al. The head and neck cancer immune landscape and its immunotherapeutic implications. 2016; 1(17): e89829. doi: 10.1172/jci.insight.89829.
    Search in Google ScholarBack to article
  22. Davis ZB, Vallera DA, Miller JS, Felices M. Natural killer cells unleashed: Checkpoint receptor blockade and BiKE/TriKE utilization in NK-mediated anti-tumor immunotherapy. Semin Immunol. 2017; 31: 64-75. doi:10.1016/j.smim.2017.07.011.
    Search in Google ScholarBack to article
  23. Freud AG, Mundy-Bosse BL, Yu J, Caligiuri MA. The Broad Spectrum of Human Natural Killer Cell Diversity. Immunity. 2017; 47(5): 820-33. doi: 10.1016/j.immuni.2017.10.008.
    Search in Google ScholarBack to article
  24. Jurisevic M, Jagic N, Gajovic N, Arsenijevic A, Jovanovic M, Milovanovic M, et al. O,O’-diethyl-(S,S)-ethylenediamine-N,N’-di-2-(3-cyclohexyl) propanoate dihydrochloride enhances influx of effective NK and NKT cells in murine breast cancer. Vojnosanit Pregl. 2020; 77(7): 715–723 doi:10.2298/VSP180723149J.
    Search in Google ScholarBack to article
  25. Gajovic N, Jurisevic M, Pantic J, Radosavljevic G, Arsenijevic N, Lukic ML, et al. Attenuation of NK cells facilitates mammary tumor growth in streptozotocin-induced diabetes in mice. Endocr Relat Cancer 2018; 25(4): 493-507.
    Search in Google ScholarBack to article
  26. Keenan TE, Tolaney SM. Role of Immunotherapy in Triple-Negative Breast Cancer. J Natl Compr Canc Netw. 2020; 18(4): 479-489. doi: 10.6004/jnccn.2020.7554.
    Search in Google ScholarBack to article
  27. Liu Q, Cheng R, Kong X, Wang Z, Fang Y, Wang J. Molecular and Clinical Characterization of PD-1 in Breast Cancer Using Large-Scale Transcriptome Data. Front Immunol. 2020; 11: 558757. doi: 10.3389/fimmu. 2020.558757.
    Search in Google ScholarBack to article
  28. Dong W, Wu X, Ma S, Wang Y, Nalin AP, Zhu Z, et al. The Mechanism of Anti-PD-L1 Antibody Efficacy against PD-L1-Negative Tumors Identifies NK Cells Expressing PD-L1 as a Cytolytic Effector. Cancer Discov. 2019; 9(10): 1422-1437. doi: 10.1158/2159-8290.CD-18-1259.
    Search in Google ScholarBack to article
  29. Neo SY, Yang Y, Record J, Ma R, Chen X, Chen Z, et al. CD73 immune checkpoint defines regulatory NK cells within the tumor microenvironment. J Clin Invest. 2020; 130(3): 1185-1198. doi: 10.1172/JCI128895.
    Search in Google ScholarBack to article
  30. Morandi F, Horenstein AL, Chillemi A, Quarona V, Chiesa S, Imperatori A, et al. CD56brightCD16− NK cells produce adenosine through a CD38-mediated pathway and act as regulatory cells inhibiting autologous CD4+ T cell proliferation. J Immunol. 2015; 195(3): 965–972. doi: 10.4049/jimmunol.1500591.
    Search in Google ScholarBack to article
  31. Tian W, Wang L, Yuan L, Duan W, Zhao W, Wang S, et al. A prognostic risk model for patients with triple negative breast cancer based on stromal natural killer cells, tumor-associated macrophages and growth-arrest specific protein 6. Cancer Sci. 2016; 107(7): 882–889. doi: 10.1111/cas.12964.
    Search in Google ScholarBack to article
  32. Zwirner NW, Domaica CI, Fuertes MB. Regulatory functions of NK cells during infections and cancer. J Leukoc Biol. 2021; 109(1): 185-194. doi: 10.1002/JLB.3MR0820-685R.
    Search in Google ScholarBack to article
  33. Zhang H, Li Y, Liu X, Liang Z, Yan M, Liu Q, et al. ImmTAC/Anti-PD-1 antibody combination to enhance killing of cancer cells by reversing regulatory T-cell-mediated immunosuppression. Immunology. 2018; 155(2): 238-250. doi: 10.1111/imm.12954.
    Search in Google ScholarBack to article
  34. Wu D, Liu Y, Pang N, Sun M, Wang X, Haridia Y, et al. PD-1/PD-L1 pathway activation restores the imbalance of Th1/Th2 and treg/Th17 cells subtypes in immune thrombocytopenic purpura patients. Medicine (Baltimore). 2019; 98(43): e17608. doi: 10.1097/MD.000000 0000017608.
    Search in Google ScholarBack to article
  35. Dong MB, Wang G, Chow RD, Ye L, Zhu L, Dai X, et al. Systematic Immunotherapy Target Discovery Using Genome-Scale In Vivo CRISPR Screens in CD8 T Cells. Cell. 2019; 178(5): 1189-1204.e23. doi: 10.1016/j.cell.2019.07.044.
    Search in Google ScholarBack to article
  36. Amatya N, Garg AV, Gaffen SL. IL-17 Signaling: The Yin and the Yang. Trends Immunol. 2017; 38(5): 310- 322. doi: 10.1016/j.it.2017.01.006.
    Search in Google ScholarBack to article
  37. Borrego F, Robertson MJ, Ritz J, Pena J, Solana R. CD69 is a stimulatory receptor for natural killer cell and its cytotoxic effect is blocked by CD94 inhibitory receptor. Immunology 1999; 97(1): 159–165.
    Search in Google ScholarBack to article
  38. Wang Z, Tan F. The blockade of PD-1/PD-L1 pathway promotes the apoptosis of CD19+ CD25+ Bregs and suppresses the secretion of IL-10 in patients with allergic rhinitis. Scand J Immunol. 2020; 91(2): e12836. doi: 10.1111/sji.12836.
    Search in Google ScholarBack to article
  39. Prasad S, Hu S, Sheng WS, Chauhan P, Lokensgard JR. Reactive glia promote development of CD103+ CD69+ CD8+ T-cells through programmed cell death-ligand 1 (PD-L1). Immun Inflamm Dis. 2018; 6(2): 332-344. doi: 10.1002/iid3.221.
    Search in Google ScholarBack to article
  40. Gao Z, Feng Y, Xu J, Liang J. T-cell exhaustion in immune-mediated inflammatory diseases: New implications for immunotherapy. Front Immunol. 2022; 13: 977394. doi: 10.3389/fimmu.2022.977394.
    Search in Google ScholarBack to article
DOI: https://doi.org/10.2478/eabr-2023-0005 | Journal eISSN: 2956-2090 | Journal ISSN: 2956-0454
Journal RSS Feed
Language: English
Submitted on: Mar 8, 2023
|
Accepted on: Jun 26, 2023
|
Published on: Aug 1, 2023
Published by: University of Kragujevac, Faculty of Medical Sciences
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
PD-1,
NK cells,
cytotoxic T cells,
mammary carcinoma
Related subjects:
Medicine,
Clinical medicine,
Clinical medicine, other

© 2023 Sanja Tripković, Miodrag Jocić, Isidora Stanisavljević, Marina Jovanović, Milena Jurišević, Andjela Petrović, Milan Jovanović, Boško Milev, Veljko Marić, Marina Jovanović, published by University of Kragujevac, Faculty of Medical Sciences
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

AHEAD OF PRINT